April 02, 2025 – AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)
April 23, 2024 – AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease
LSX World Congress : Life Science Partnering & Investment
28-30 April 2025 – One of the European’s leading partnering, strategy, and investment event – London UK
